Your browser doesn't support javascript.
loading
Anti-PD1 in the wonder-gut-land.
Vetizou, Marie; Trinchieri, Giorgio.
Affiliation
  • Vetizou M; Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Trinchieri G; Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Cell Res ; 28(3): 263-264, 2018 03.
Article in En | MEDLINE | ID: mdl-29336431
ABSTRACT
After the initial success of cancer immunotherapy using immune checkpoint blockers, the challenge is to understand why only a minority of patients respond to the therapy and to increase the rate of response. Three recent papers now report that the gut microbiota modulates the response to anti-PD1 therapy in patients with epithelial cancers or melanoma.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Neoplasms, Glandular and Epithelial / Gastrointestinal Microbiome / Melanoma Limits: Humans Language: En Journal: Cell Res Year: 2018 Type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Neoplasms, Glandular and Epithelial / Gastrointestinal Microbiome / Melanoma Limits: Humans Language: En Journal: Cell Res Year: 2018 Type: Article Affiliation country: United States